Therapix Biosciences Signs Term Sheet for the Transfer of Non-Pain …

TEL AVIV, Israel, July 12, 2018  /PRNewswire/ — Therapix Biosciences Ltd. (Nasdaq: TRPX) (“Therapix”) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced that today that it has signed a non-binding term sheet with CURE Pharmaceutical (OTCQB: CURR) (“CURE”), an innovative drug delivery and development company, for the transfer to CURE of the non-pain assets of Therapix, subject to the fulfillment of the certain conditions. 

The term sheet entered into is non-binding and subject to ongoing due diligence and the entry into of definitive agreements and the fulfillment of certain more at

Leave a Reply